general conditions of use
privacy statement
imprint
© 2007 Bayer HealthCare Pharmaceuticals

 


Physician Support
Chemotherapy
   
     
 

Viadur is indicated in the palliative treatment of advanced prostate cancer. Bayer is not responsible for, and does not endorse, any of the information found on this page.

Treatment Options

Chemotherapy
  Cryosurgery
  Hormone therapy
  Radiation therapy
  Radical prostatectomy
  Transurethral resection of the prostate (TURP)
  Watchful waiting

There are many treatments for prostate cancer. The best one for you depends on a number of factors. These include your age, your overall health, and the stage and grade of your cancer.

Be sure to discuss the possible benefits, risks and side effects with each option. The sections here outline some of the general risks and side effects. However, your doctor is the best source of information on your condition. Before you and your doctor select any treatment approach, risks and benefits should be thoroughly discussed.Take the time to research all of your treatment options. Consider getting a second opinion before making a final decision. The most common treatment options for prostate cancer include watchful waiting, radiation, and hormone therapy.

Chemotherapy

Chemotherapy involves injecting drugs into a vein or taking the drug orally. These drugs kill cancer cells, but they also damage some normal cells.1 The doctor must maintain a delicate balance of chemotherapy doses, making them strong enough to kill the cancer cells but not strong enough to destroy many healthy cells.2 Prostate cancer cells grow very slowly; consequently research has shown chemotherapy to be of limited effect because the drugs cannot differentiate slow-growing cancer cells from normal cells.3

What are possible side effects: Potential side effects vary among different drugs and patients. The side effects range from minimal – vomiting/nausea, hair loss, mouth sores, and fatigue – to more severe – such as bone marrow suppression.4

Who makes a good candidate: Men who tried other types of treatments, but the cancer continued to grow, or those in an advanced stage of cancer, or when the cancer has grown outside the prostate gland and have failed on hormone therapy.5

Viadur is indicated in the palliative treatment of advanced prostate cancer.

 


Printer-Friendly Version


References

Important Safety Considerations
Viadur is contraindicated in patients with hypersensitivity to Gn-RH, Gn-RH agonist analogs, or any of the components in Viadur.

Viadur is contraindicated in women and pediatric patients and was not studied in women or children.

Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience a worsening of symptoms or onset of new symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, and spinal cord compression.

The most comment systemic side effects were hot flashes (67.9%), asthenia (7.6%), gynecomastia (6.9%), depression (5.3%), and sweating (5.3%). The most common local side effects were bruising (34.6%) and burning (5.6%).


Distributed and Marketed by:

Manufactured by:

Bayer HealthCare Pharmaceuticals
6 West Belt, Wayne, NJ 07470 USA

© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation.

The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.